{"id":"NCT02584855","sponsor":"Eli Lilly and Company","briefTitle":"A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis","officialTitle":"A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-09-14","primaryCompletion":"2018-10-30","completion":"2018-10-30","firstPosted":"2015-10-23","resultsPosted":"2019-11-15","lastUpdate":"2019-11-15"},"enrollment":394,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Psoriatic Arthritis"],"interventions":[{"type":"DRUG","name":"Ixekizumab","otherNames":["LY2439821"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Ixekizumab Open Label","type":"EXPERIMENTAL"},{"label":"Ixekizumab","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"IXE80Q2W Non-randomized","type":"EXPERIMENTAL"}],"summary":"The main purpose of this study is to evaluate the safety and long-term efficacy of ixekizumab compared to placebo in participants with active psoriatic arthritis.","primaryOutcome":{"measure":"Double-Blind Withdrawal Period: Time to Relapse (No Longer Meeting Coates Criteria for Minimal Disease Activity [MDA])","timeFrame":"Double Blind Randomization through Week 104 (or Early Termination or Relapse)","effectByArm":[{"arm":"Ixekizumab","deltaMin":null,"sd":null},{"arm":"Placebo","deltaMin":22.29,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":8},"locations":{"siteCount":106,"countries":["United States","Bulgaria","Czechia","Estonia","Mexico","Poland","Russia","Slovakia","South Africa","Spain","Ukraine","United Kingdom"]},"refs":{"pmids":["35393269","33682378","31964419"],"seeAlso":["http://www.lillytrialguide.com/EN/studies/arthritis/rhbf"]},"adverseEventsSummary":{"seriousAny":{"events":20,"n":394},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Injection site reaction","Bronchitis","Alanine aminotransferase increased"]}}